JAK-STAT1/2 Pathway Activity Determination Using Gene Expression Panels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a precise and accurate way to determine the activity level of the JAK-STAT1/2 cellular signaling pathway, which is crucial for diagnosing and treating cancers and immune disorders, as existing assays cannot assess the functional state of this pathway effectively.
Innovation Solution
A method and apparatus that calculate the activity level of the JAK-STAT1/2 transcription factor element by measuring the expression levels of a unique set of target genes using a calibrated pathway model, allowing for the differentiation between IFN type I and type II activities, thereby determining the pathway's activity status.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing assays are used to determine pathway activity, then the diagnostic process is simple, but the measurement precision and accuracy of JAK-STAT1/2 pathway activity is insufficient
Solution Approach 1:
The patent segments the JAK-STAT1/2 pathway assessment into distinct functional modules: type I interferon response measurement, type II interferon response measurement, and integrated pathway activity calculation. Each module uses specific gene expression panels and computational algorithms, allowing precise measurement of different pathway components while maintaining manageable assay complexity through modular design
Solution Approach 2:
The patent transforms the measurement approach by changing from direct pathway activity measurement to indirect gene expression level measurement. By measuring the expression levels of multiple target genes (ISG54, IFIT1, CXCL10 for type I; IFI27, OAS1, MX1 for type II) and applying computational models, the assay achieves high measurement precision while keeping the experimental protocol relatively simple
2Measurement precision
If a unique combination of target genes is measured, then the differentiation between IFN type I and type II activities is improved, but the quantity of genes to be measured increases
Solution Approach 1:
The patent applies local quality by selecting specific gene subsets that are locally optimized for detecting particular pathway activities. Different gene combinations are used for type I versus type II interferon responses, with each gene panel tailored to maximize sensitivity and specificity for its intended pathway, thereby achieving high measurement precision without unnecessarily increasing the total number of genes measured
Solution Approach 2:
The patent creates a universal assay platform that can measure both type I and type II interferon pathway activities using a integrated gene expression panel. The same basic assay infrastructure (RNA extraction, reverse transcription, expression measurement) serves multiple detection purposes, and the computational framework universally processes data from both pathway types, reducing overall complexity despite measuring multiple genes
3Measurement precision
If a calibrated pathway model is used to calculate activity levels, then the determination of disease state is more accurate, but the computational processing complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-calibrating the pathway model using training data from patients with known disease states and pathway activities. The calibration parameters, weightings, and thresholds are established beforehand through statistical analysis of reference datasets, allowing the model to be applied to new samples with high accuracy without requiring complex real-time computation or iterative calibration during actual testing
Solution Approach 2:
The patent uses computational copying by creating a virtual representation of the biological pathway through mathematical models that replicate pathway behavior. The calibrated pathway model copies the essential dynamics and relationships of the JAK-STAT1/2 signaling network, allowing accurate disease state determination through computational analysis rather than complex wet-lab experiments
Data Source
AI summary
A bioinformatics process which provides an improved means to detect a JAK-STAT1/2 cellular signaling pathway in a subject, such as a human, based on the expression levels of at least three unique target genes of the JAK-STAT1/2 cellular signaling pathway measured in a sample. The invention includes an apparatus comprising a digital processor configured to perform such a method, a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and a computer program comprising program code means for causing a digital processing device to perform such a method. Kits are also provided for measuring expression levels of unique sets of JAK-STAT1/2 cellular signaling pathway target genes.